110 related articles for article (PubMed ID: 26956669)
1. CRM1 Inhibition Promotes Cytotoxicity in Ewing Sarcoma Cells by Repressing EWS-FLI1-Dependent IGF-1 Signaling.
Sun H; Lin DC; Cao Q; Guo X; Marijon H; Zhao Z; Gery S; Xu L; Yang H; Pang B; Lee VK; Lim HJ; Doan N; Said JW; Chu P; Mayakonda A; Thomas T; Forscher C; Baloglu E; Shacham S; Rajalingam R; Koeffler HP
Cancer Res; 2016 May; 76(9):2687-97. PubMed ID: 26956669
[TBL] [Abstract][Full Text] [Related]
2. Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma.
Niedan S; Kauer M; Aryee DN; Kofler R; Schwentner R; Meier A; Pötschger U; Kontny U; Kovar H
Oncogene; 2014 Jul; 33(30):3927-38. PubMed ID: 23995784
[TBL] [Abstract][Full Text] [Related]
3. EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.
Tanner JM; Bensard C; Wei P; Krah NM; Schell JC; Gardiner J; Schiffman J; Lessnick SL; Rutter J
Mol Cancer Res; 2017 Nov; 15(11):1517-1530. PubMed ID: 28720588
[TBL] [Abstract][Full Text] [Related]
4. Association of EWS-FLI1 type 1 fusion with lower proliferative rate in Ewing's sarcoma.
de Alava E; Panizo A; Antonescu CR; Huvos AG; Pardo-Mindán FJ; Barr FG; Ladanyi M
Am J Pathol; 2000 Mar; 156(3):849-55. PubMed ID: 10702401
[TBL] [Abstract][Full Text] [Related]
5. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
[TBL] [Abstract][Full Text] [Related]
6. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
[TBL] [Abstract][Full Text] [Related]
7. Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.
Caropreso V; Darvishi E; Turbyville TJ; Ratnayake R; Grohar PJ; McMahon JB; Woldemichael GM
J Biol Chem; 2016 May; 291(19):10058-66. PubMed ID: 26961871
[TBL] [Abstract][Full Text] [Related]
8. Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells.
Agra N; Cidre F; García-García L; de la Parra J; Alonso J
PLoS One; 2013; 8(6):e66281. PubMed ID: 23750284
[TBL] [Abstract][Full Text] [Related]
9. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma.
Shi X; Zheng Y; Jiang L; Zhou B; Yang W; Li L; Ding L; Huang M; Gery S; Lin DC; Koeffler HP
Nucleic Acids Res; 2020 Nov; 48(20):11434-11451. PubMed ID: 33080033
[TBL] [Abstract][Full Text] [Related]
10. Targeted long-read sequencing of the Ewing sarcoma 6p25.1 susceptibility locus identifies germline-somatic interactions with EWSR1-FLI1 binding.
Lee OW; Rodrigues C; Lin SH; Luo W; Jones K; Brown DW; Zhou W; Karlins E; Khan SM; Baulande S; Raynal V; Surdez D; Reynaud S; Rubio RA; Zaidi S; Grossetête S; Ballet S; Lapouble E; Laurence V; Pierron G; Gaspar N; Corradini N; Marec-Bérard P; Rothman N; Dagnall CL; Burdett L; Manning M; Wyatt K; Yeager M; Chari R; Leisenring WM; Kulozik AE; Kriebel J; Meitinger T; Strauch K; Kirchner T; Dirksen U; Mirabello L; Tucker MA; Tirode F; Armstrong GT; Bhatia S; Robison LL; Yasui Y; Romero-Pérez L; Hartmann W; Metzler M; Diver WR; Lori A; Freedman ND; Hoover RN; Morton LM; Chanock SJ; Grünewald TGP; Delattre O; Machiela MJ
Am J Hum Genet; 2023 Mar; 110(3):427-441. PubMed ID: 36787739
[TBL] [Abstract][Full Text] [Related]
11. Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity.
Balestra T; Manara MC; Laginestra MA; Pasello M; De Feo A; Bassi C; Guerzoni C; Landuzzi L; Lollini PL; Donati DM; Negrini M; Magnani M; Scotlandi K
Mol Cancer Ther; 2022 Jan; 21(1):58-69. PubMed ID: 34667115
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of HDACs reduces Ewing sarcoma tumor growth through EWS-FLI1 protein destabilization.
Pedot G; Marques JG; Ambühl PP; Wachtel M; Kasper S; Ngo QA; Niggli FK; Schäfer BW
Neoplasia; 2022 May; 27():100784. PubMed ID: 35366465
[TBL] [Abstract][Full Text] [Related]
13. EWS-FLI1 employs an E2F switch to drive target gene expression.
Schwentner R; Papamarkou T; Kauer MO; Stathopoulos V; Yang F; Bilke S; Meltzer PS; Girolami M; Kovar H
Nucleic Acids Res; 2015 Mar; 43(5):2780-9. PubMed ID: 25712098
[TBL] [Abstract][Full Text] [Related]
14. NELL2-cdc42 signaling regulates BAF complexes and Ewing sarcoma cell growth.
Jayabal P; Zhou F; Lei X; Ma X; Blackman B; Weintraub ST; Houghton PJ; Shiio Y
Cell Rep; 2021 Jul; 36(1):109254. PubMed ID: 34233189
[TBL] [Abstract][Full Text] [Related]
15. USP1 Expression Driven by EWS::FLI1 Transcription Factor Stabilizes Survivin and Mitigates Replication Stress in Ewing Sarcoma.
Mallard HJ; Wan S; Nidhi P; Hanscom-Trofy YD; Mohapatra B; Woods NT; Lopez-Guerrero JA; Llombart-Bosch A; Machado I; Scotlandi K; Kreiling NF; Perry MC; Mirza S; Coulter DW; Band V; Band H; Ghosal G
Mol Cancer Res; 2023 Nov; 21(11):1186-1204. PubMed ID: 37478161
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.
Lessnick SL; Ladanyi M
Annu Rev Pathol; 2012; 7():145-59. PubMed ID: 21942527
[TBL] [Abstract][Full Text] [Related]
17. Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair.
Abeykoon JP; Wu X; Nowakowski KE; Dasari S; Paludo J; Weroha SJ; Hu C; Hou X; Sarkaria JN; Mladek AC; Phillips JL; Feldman AL; Ravindran A; King RL; Boysen J; Stenson MJ; Carr RM; Manske MK; Molina JR; Kapoor P; Parikh SA; Kumar S; Robinson SI; Yu J; Boughey JC; Wang L; Goetz MP; Couch FJ; Patnaik MM; Witzig TE
Blood; 2021 Jan; 137(4):513-523. PubMed ID: 33507295
[TBL] [Abstract][Full Text] [Related]
18. YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.
Minas TZ; Han J; Javaheri T; Hong SH; Schlederer M; Saygideğer-Kont Y; Çelik H; Mueller KM; Temel I; Özdemirli M; Kovar H; Erkizan HV; Toretsky J; Kenner L; Moriggl R; Üren A
Oncotarget; 2015 Nov; 6(35):37678-94. PubMed ID: 26462019
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial Drug Screening Identifies Ewing Sarcoma-specific Sensitivities.
Radic-Sarikas B; Tsafou KP; Emdal KB; Papamarkou T; Huber KV; Mutz C; Toretsky JA; Bennett KL; Olsen JV; Brunak S; Kovar H; Superti-Furga G
Mol Cancer Ther; 2017 Jan; 16(1):88-101. PubMed ID: 28062706
[TBL] [Abstract][Full Text] [Related]
20. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
